When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Product ownership changed from GSK to Aspen
Change to section 7 - Marketing Authrisation Holder From GlaxoSmithKline to Aspen Europe
Update to section 4.8 to add Steven Johnson Syndrome and toxic epidermal necrolysis
Section 4.8
Immune System Disorders
Uncommon: hypersensitivity reactions
Very rare: Stevens-Johnson syndrome and toxic epidermal necrolysis